Access

Letter

Nature Genetics 39, 347–351 (1 March 2007) | doi:10.1038/ng1975

High-throughput oncogene mutation profiling in human cancer

Roman K Thomas , Alissa C Baker , Ralph M DeBiasi , Wendy Winckler , Thomas LaFramboise , William M Lin , Meng Wang , Whei Feng , Thomas Zander , Laura E MacConnaill , Jeffrey C Lee , Rick Nicoletti , Charlie Hatton , Mary Goyette , Luc Girard , Kuntal Majmudar , Liuda Ziaugra , Kwok-Kin Wong , Stacey Gabriel , Rameen Beroukhim , Michael Peyton , Jordi Barretina , Amit Dutt , Caroline Emery , Heidi Greulich , Kinjal Shah , Hidefumi Sasaki , Adi Gazdar , John Minna , Scott A Armstrong , Ingo K Mellinghoff , F Stephen Hodi , Glenn Dranoff , Paul S Mischel , Tim F Cloughesy , Stan F Nelson , Linda M Liau , Kirsten Mertz , Mark A Rubin , Holger Moch , Massimo Loda , William Catalona , Jonathan Fletcher , Sabina Signoretti , Frederic Kaye , Kenneth C Anderson , George D Demetri , Reinhard Dummer , Stephan Wagner , Meenhard Herlyn , William R Sellers , Matthew Meyerson & Levi A Garraway

Systematic efforts are underway to decipher the genetic changes associated with tumor initiation and progression. However, widespread clinical application of this information is hampered by an inability to identify critical genetic events across the spectrum of human tumors with adequate sensitivity and scalability.